Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Natera, Inc.NTRA · Entity 2635 | PRESIDENT, CLINICALDIAGNOSTICS | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Natera, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,914 |
Ending reported balance
After 2026-10-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Sale · Disposed 200 · Balance 109,714 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-10-01 · Sale · Disposed 954 · Balance 108,760 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-01 · Sale · Disposed 1,846 · Balance 106,914 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 5, 2026 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 80 | $228.50 | $18,280.00 |
DisclosureSEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,406 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,200 | $237.66 | $285,194.88 |
DisclosureSEC source: 0002010019-26-000005 · form4-01292026_080103.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,486 F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,013 | $240.53 | $243,658.21 |
DisclosureSEC source: 0002010019-26-000005 · form4-01292026_080103.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,686 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 293 | $235.00 | $68,855.00 |
DisclosureSEC source: 0002010019-26-000004 · form4-01222026_090103.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,699 F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 23,205 | $234.74 | $5,447,104.57 |
DisclosureSEC source: 0002010019-26-000004 · form4-01222026_090103.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,992 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 44,698 | $0.00 | $0.00 |
DisclosureSEC source: 0002010019-26-000003 · form4-01162026_090105.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,197 F1 · shares: On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 44,698 shares of Common Stock. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,659 | $229.43 | $380,619.89 |
DisclosureSEC source: 0002010019-26-000002 · form4-01062026_090103.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,499 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.94 to $229.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,292 | $228.33 | $295,001.58 |
DisclosureSEC source: 0002010019-26-000002 · form4-01062026_090103.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,158 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.8050 to $228.76 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | GiftCommon Stock | 115 | $0.00 | $0.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 5 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,450 F1 · shares: Represents a charitable contribution by the Reporting Person. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 13,500 | $9.59 | $129,465.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 4,692 | $230.76 | $1,082,714.19 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,065 F2 · shares: The sale of these shares was effected in order to cover the exercise price and satisfy tax withholding and remittance obligations in connection with the exercise of expiring options. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 8,876 | $9.59 | $85,120.84 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | GiftCommon Stock | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,881 F1 · shares: Represents a charitable contribution by the Reporting Person. Read SEC document |
| December 10, 2025 Filed Dec 17, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 22,376 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · derivative · entry 6 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,125 Underlying: Common Stock · 22,376 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The options exercised were composed of 13,500 incentive stock options and 8,876 non-qualified stock options. F4 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 474 | $239.53 | $113,535.37 |
DisclosureSEC source: 0002010019-25-000014 · form4-12032025_081203.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,061 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $239.44 to $239.64 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,527 | $238.24 | $363,796.76 |
DisclosureSEC source: 0002010019-25-000014 · form4-12032025_081203.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,535 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.86 to $238.81 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 250 | $237.77 | $59,443.25 |
DisclosureSEC source: 0002010019-25-000014 · form4-12032025_081203.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,062 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.7550 to $237.7850 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 749 | $237.23 | $177,683.40 |
DisclosureSEC source: 0002010019-25-000014 · form4-12032025_081203.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,312 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.71 to $237.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 100 | $199.74 | $19,974.00 |
DisclosureSEC source: 0002010019-25-000012 · form4-11042025_091102.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,061 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,450 | $199.10 | $288,698.34 |
DisclosureSEC source: 0002010019-25-000012 · form4-11042025_091102.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,161 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.71 to $199.42 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,450 | $198.03 | $287,137.70 |
DisclosureSEC source: 0002010019-25-000012 · form4-11042025_091102.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,611 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.28 to $198.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,198 | $191.46 | $229,371.36 |
DisclosureSEC source: 0002010019-25-000010 · form4-10292025_091003.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,061 F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| October 27, 2025 Filed Oct 30, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,008 | $192.32 | $193,862.59 |
DisclosureSEC source: 0002010019-25-000010 · form4-10292025_091003.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,259 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 292 | $187.95 | $54,881.40 |
DisclosureSEC source: 0002010019-25-000008 · form4-10222025_091006.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,267 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 780 | $160.70 | $125,346.62 |
DisclosureSEC source: 0002010019-25-000006 · form4-10012025_091008.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,559 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.42 to $161.39 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,816 | $159.91 | $290,402.19 |
DisclosureSEC source: 0002010019-25-000006 · form4-10012025_091008.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,339 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.40 to $160.38 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 404 | $158.96 | $64,220.08 |
DisclosureSEC source: 0002010019-25-000006 · form4-10012025_091008.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,155 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.39 to $159.2950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2025 Filed Sep 18, 2025 00:05 UTC | Natera, Inc. NTRA · Entity 2635 | GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0002010019-25-000003 · form4-09172025_080901.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,559 F1 · shares: Represents a charitable contribution by the Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 6, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,210 | $167.71 | $202,934.55 |
DisclosureSEC source: 0001415889-25-023825 · form4-09052025_090901.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,859 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.41 to $168.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 6, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 500 | $166.39 | $83,195.00 |
DisclosureSEC source: 0001415889-25-023825 · form4-09052025_090901.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,069 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.09 to $166.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 6, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,290 | $165.69 | $213,735.20 |
DisclosureSEC source: 0001415889-25-023825 · form4-09052025_090901.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,569 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.09 to $166.06 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2025 Filed Aug 16, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 8 | $155.42 | $1,243.40 |
DisclosureSEC source: 0001415889-25-022148 · form4-08152025_090803.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,859 F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021. Read SEC document |
| August 14, 2025 Filed Aug 16, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 867 | $155.46 | $134,783.82 |
DisclosureSEC source: 0001415889-25-022148 · form4-08152025_090803.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,867 F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021. Read SEC document |
| August 12, 2025 Filed Aug 16, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022148 · form4-08152025_090803.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,734 F1 · shares: On October 22, 2021, the Reporting Person was granted Restricted Stock Units ("RSUs") covering 10,000 shares of Common Stock which vest in tranches upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On August 12, 2025, the achievement of criteria was certified for the vesting of RSUs covering 1,675 shares of Common Stock. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 100 | $134.08 | $13,408.00 |
DisclosureSEC source: 0001415889-25-021139 · form4-08052025_090801.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,059 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,326 | $133.31 | $176,768.66 |
DisclosureSEC source: 0001415889-25-021139 · form4-08052025_090801.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,159 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.96 to $133.80 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,574 | $132.45 | $208,480.71 |
DisclosureSEC source: 0001415889-25-021139 · form4-08052025_090801.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,485 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.9350 to $132.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 28, 2025 Filed Jul 31, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,206 | $139.81 | $308,417.11 |
DisclosureSEC source: 0001415889-25-020663 · form4-07302025_090705.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,059 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 291 | $139.29 | $40,533.39 |
DisclosureSEC source: 0001415889-25-020156 · form4-07222025_090703.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,265 F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 291 | $167.79 | $48,826.89 |
DisclosureSEC source: 0001415889-25-019390 · form4-07032025_090703.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,205 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,109 | $167.25 | $352,730.46 |
DisclosureSEC source: 0001415889-25-019390 · form4-07032025_090703.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,496 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.64 to $167.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 200 | $165.99 | $33,197.00 |
DisclosureSEC source: 0001415889-25-019390 · form4-07032025_090703.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,605 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.62 to $166.35 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 400 | $163.88 | $65,550.56 |
DisclosureSEC source: 0001415889-25-019390 · form4-07032025_090703.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,805 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.55 to $164.08 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 100 | $159.12 | $15,912.00 |
DisclosureSEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,205 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 465 | $158.37 | $73,642.89 |
DisclosureSEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,305 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.88 to $158.5450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,145 | $157.23 | $180,028.12 |
DisclosureSEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,770 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.74 to $157.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,290 | $156.30 | $201,629.06 |
DisclosureSEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,915 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.73 to $156.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2025 Filed Jul 23, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,649 | $156.85 | $258,646.47 |
DisclosureSEC source: 0001415889-25-020156 · form4-07222025_090703.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,556 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on June 10, 2022. Read SEC document |
| May 01, 2025 Filed May 3, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 331 | $152.04 | $50,325.24 |
DisclosureSEC source: 0001415889-25-011882 · form4-05022025_090504.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,205 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| May 01, 2025 Filed May 3, 2025 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 908 | $151.30 | $137,378.95 |
DisclosureSEC source: 0001415889-25-011882 · form4-05022025_090504.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,536 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.97 to $151.5450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.